ET501

ET501 is a preclinical-stage gene therapy being developed by Expression Therapeutics for the treatment of solid tumors, specifically neuroendocrine tumors (PTK7+ neuroendocrine carcinomas) and neuroblastoma. The therapy targets Protein Tyrosine Kinase 7 (PTK7), a cell surface protein that is frequently overexpressed in various cancers and is associated with tumor progression and poor prognosis. While the specific genetic payload or delivery mechanism (such as a viral vector or non-viral system) has not been publicly detailed, ET501 is part of a pipeline focused on leveraging advanced expression platforms to address difficult-to-treat malignancies.